X
No Ads. No Trackers. No Kidding! (Learn More)
Loading...
Tags:
After facing intense criticism, Biogen goes on defense, blames "misinformation." [Read More]
The Cambridge biotech vigorously defended its actions that led to the approval of Aduhelm, saying scientific data indicated the medicine will likely help patients and... [Read More]
Biogen is under fire once again because of their controversial Alzheimer's drug, Aduhelm. An online survey published by the company recommends people for a cognitive... [Read More]
House panel presses FDA on inspections abroad — Biogen official defends Alzheimer's drug approval... [Read More]
Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you? [Read More]
and controversial - Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its... [Read More]
BIIB earnings call for the period ending June 30, 2021. [Read More]
Biogen R&D chief says that misinformation is at the heart of the controversy surrounding Aduhelm, his companies newly approved Alzheimer's drug. [Read More]
Thumbnail
Biogen executives sought to assure investors that the science behind its newly approved Alzheimer's disease drug is firm despite ongoing questions about... [Read More]
Biogen executives sought to assure investors that the science behind its newly approved Alzheimer's disease drug is firm despite ongoing questions about whether the drug... [Read More]
In Thursday's episode of TheStreet Live, Jim Cramer discusses earnings from AT&T, Biogen, and Southwest, cryptocurrency and much more. [Read More]
Market News... [Read More]
This couple took prompt action following symptoms of mild cognitive impairment, an early stage of Alzheimer's that doctors say is a crucial window... [Read More]
The company pushed back against criticism of the drug's effectiveness and approval, saying trial data supported use. [Read More]
Jim Cramer breaks down his latest thoughts on Biogen's controversial Alzheimer's drug. [Read More]
The figure was below the $6.3 million analysts surveyed by FactSet expected, but the gap is relatively small for a drug expected to bring in... [Read More]
The figure was below the $6.3 million analysts surveyed by FactSet expected, but the gap is relatively small for a drug expected to bring in... [Read More]
The drug from Biogen, called Aduhelm, is expected to generate billions in sales. It could also strain Medicare's budget within a few years. [Read More]
Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021. [Read More]
Jim Cramer discusses earnings from Biogen, AT&T, the airlines and the rails, as well as cryptocurrency and Uber in Thursday's TheStreet Live video interview. [Read More]
Loading...
Save As
Preview
Preview